|Bid||49.50 x 400|
|Ask||49.70 x 300|
|Day's Range||49.35 - 49.62|
|52 Week Range||49.35 - 49.62|
|Beta (3Y Monthly)||N/A|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
Investors with a long-term horizong may find it valuable to assess Exactech Inc’s (NASDAQ:EXAC) earnings trend over time and against its industry benchmark as opposed to simply looking at aRead More...
TPG Capital acquires Exactech (EXAC) with a view to cash in on its resources and gain a foothold in the orthopedics market.
Exactech, Inc. , a leading developer and producer of orthopaedic implant devices and surgical instrumentation for extremities and large joints, is pleased to announce the successful completion of the previously announced merger agreement with TPG Capital, pursuant to which TPG has acquired all of the issued and outstanding common stock of Exactech.
Exactech , a leading developer and producer of orthopaedic implant devices and surgical instrumentation for extremities and large joints, today announced that at a Special Meeting of Shareholders held earlier today, Exactech’s shareholders approved the previously announced merger agreement with TPG Capital and certain of its affiliates, and approved the other two proposals described in Exactech’s proxy ...
Moody's Investors Service, ("Moody's") assigned a B2 Corporate Family Rating and a B2-PD Probability of Default Rating to Osteon Merger Sub, Inc. ("Osteon"). Moody's also assigned a ...
NEW YORK, NY / ACCESSWIRE / December 28, 2017 / The following statement is being issued by Levi & Korsinsky, LLP: To: All Persons or Entities who purchased Exactech, Inc. ("Exactech" or the "Company") ...
Andrews & Springer LLC, a boutique securities class action law firm focused on representing shareholders nationwide, is investigating potential breach of fiduciary duty claims against the Board of Directors of Exactech, Inc.